Erring drug companies to face stricter action as rules to improve mfg standards come into effect today

Drugmakers in India may soon face stricter enforcement of quality standards. The revised Schedule M, which details manufacturing practices and quality requirements, will come into effect on January 1. The industry had expected an extension but must now comply. The enforcement includes audits and risk-based inspections to ensure compliance with the new standards.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6A5mI4D
via IFTTT

Read More

IBC turns lifeline for hospitals: Investors snap up distressed healthcare firms

Promoter-driven firms and hospital operators are targeting stressed healthcare assets through insolvency processes due to lower valuations. Despite risks, the post-pandemic interest in healthcare is high, driven by insurance penetration and government schemes, leading to significant acquisitions and resolution cases.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sqRwNmy
via IFTTT

Read More

#25 For 2025: What will it take to ease the pain of medical inflation and rising premium payments?

Health insurance premiums are projected to rise by 10-15% in 2025 due to increasing medical costs, higher claims frequency, and regulatory changes. Medical inflation and increased hospital tariffs are pushing costs higher. Changes by IRDAI are making health insurance more accessible but adding strain to insurance finances. NHCX and billing practices need improvement.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tqzDMnY
via IFTTT

Read More

Will we succeed in making low medical bills a reality?

Healthcare costs are expected to decline over the next decade due to digital health platforms and cost-effective medical equipment. Indian pharmaceutical companies will increase production, while the insurance sector liberalization has allowed the launch of affordable health insurance. India is also set to become a major provider of healthcare professionals globally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/V9sJOgv
via IFTTT

Read More

Why investing in healthcare is vital?

Technological advancements in cancer care offer immense investment potential in India, particularly in early detection and preventive solutions. Companies like Previu Health aim to transform diagnostics with their multi-cancer detection technology while expanding access and affordability nationwide, making healthcare investments both profitable and impactful.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tMHQEzl
via IFTTT

Read More

Blackstone, Carlyle and other PEs submit bids to unlock Access' majority stake

Several global private equity funds, including Blackstone and Carlyle, have expressed interest in acquiring a majority stake in Access Healthcare. The company, specializing in revenue cycle management services, is expected to be valued at $1.4-1.5 billion. Access Healthcare, founded by Anurag Jain, employs 27,000 people globally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/M54OBjw
via IFTTT

Read More

Home delivery of medicines from Railway-run hospitals in works

Indian Railways is planning to work with online pharmacy platforms to enable home delivery of medicines from its hospitals. RailTel aims to invite bids in January 2025 for discount-based services. This initiative, in collaboration with the health ministry, could extend to all government hospitals if successful.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eTgLGbf
via IFTTT

Read More

Bengaluru: Trustwell Hospitals plans 100-bed expansion

Bengaluru-based Trustwell Hospitals expands to a 250-bed facility with an investment of Rs 25 crore, adding 100 new beds and 150 jobs. The hospital plans to introduce new specialities and two additional units in South Bengaluru. The current facility, established by veteran healthcare professionals, has invested Rs 100 crore so far.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WtGy7Lk
via IFTTT

Read More

“Fear of heart disease” drives surge in cardiac CT scans among young adults after recent celebrity deaths

Rising heart attack cases among young adults have prompted a surge in cardiac CT scans, particularly after the deaths of well-known personalities. Cardiologists and radiologists are divided over the necessity of such tests, with concerns about unnecessary radiation exposure. Experts attribute the trend to lifestyle factors, family history, and the increasing prevalence of heart disease among people under 50.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oH0KArI
via IFTTT

Read More

RIL buys Karkinos Health for Rs 375 crore

Reliance Industries has acquired technology-led oncology platform Karkinos Healthcare for ₹375 crore. The acquisition was made through its subsidiary, Reliance Strategic Business Ventures, in an all-cash deal. Karkinos has become a step down wholly-owned subsidiary of Reliance Industries following the subscription and allotment of equity shares, and cancellation of existing shares held by erstwhile shareholders.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Yt84QZ3
via IFTTT

Read More

People single all their lives might have low life satisfaction, finds first-of-its-kind study

New research from the University of Bremen shows lifelong singles may have lower life satisfaction and different personality traits than partnered individuals. These singles are often less extraverted, less conscientious and less open to new experiences. The study suggests the need for better support networks catered to older singles facing health and financial issues.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uF5hnoV
via IFTTT

Read More

111 drug samples tested in November found 'not of standard quality'

In November, the Central Drugs Standard Control Organisation (CDSCO) identified 41 drug samples as not of standard quality (NSQ), while state drug testing laboratories identified 70 NSQ samples. Additionally, two drug samples were found to be spurious, made by unauthorized manufacturers. Authorities regularly collaborate with state regulators to remove such drugs from the market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yuXw73d
via IFTTT

Read More

Low conviction rate of cases related to fake drugs a concern

The parliamentary standing committee on chemicals and fertilisers has highlighted a concerning 5.9% conviction rate for spurious or adulterated drug cases in India. From 2015-19, 593 drug samples were spurious, and 9,266 were substandard, yet only 35 convictions were made. The committee recommended stringent, time-bound punishments for such offences.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GNiHSJv
via IFTTT

Read More

Addressing “Metabolic Syndrome”: Key to tackling type-2 diabetes in India

India is facing an alarming rise in metabolic syndrome, which is associated with Type-2 diabetes and other severe health issues. Factors like abdominal obesity, hypertension, and low HDL cholesterol increase the risk of insulin resistance and cardiovascular diseases. Lifestyle modifications can help in reducing these risks and improve overall health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MCmzUWV
via IFTTT

Read More

Chemists selling spurious meds may face prosecution

The government has established a committee to create rules for prosecuting chemists and retailers selling spurious drugs. This initiative aims to tackle the issue of substandard drugs being sold despite valid invoices from other states. The committee's report is expected within one month.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pJgivIx
via IFTTT

Read More

Mankind Pharma inks licensing pact with Innovent to commercialise Sintilimab in India

Mankind Pharma Ltd and Innovent Biologics have partnered to license and commercialise the cancer immunotherapy drug Sintilimab in India. They aim to enhance cancer treatment and patient access to innovative therapies. Mankind Pharma plans to seek regulatory approval in 2024 and perform essential clinical trials in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ojmvWJK
via IFTTT

Read More

Akums enters into Rs 1750 crore contract to supply pharma products to Europe

Akums Drugs & Pharmaceuticals has signed a long-term contract worth Rs 1760 crore with an unnamed global pharmaceutical company to manufacture and supply oral liquid formulations in Europe. They will receive an upfront payment of €100 million and expect commercial supply from 2027 to 2032. Approval processes are anticipated to be completed by 2026.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9VPS6wg
via IFTTT

Read More

Drinking tea, coffee linked to lower risk of head and neck cancer: Study

Drinking 3-4 cups of coffee daily is linked to a 17% lower risk of head and neck cancers, and one cup of tea daily reduces the risk by 9%, according to a review. The bioactive compounds in these beverages, including caffeine, may contribute to this reduced cancer risk.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ztkhjCJ
via IFTTT

Read More

Mankind Pharma partners with Innovent to aid cancer treatment in India

Mankind Pharma has partnered with Innovent Biologics to bring sintilimab, a PD-1 immunotherapy, to India. The drug treats various cancers and improves patient access to innovative therapies. Mankind Pharma will manage registration, import, marketing, and distribution, while Innovent will handle manufacturing and supply. This collaboration aims to transform oncology care in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7SOuLi9
via IFTTT

Read More

This anti-diabetic drug used for weight loss has been approved by US FDA: When will India see its launch?

The FDA approves Zepbound, originally used for type 2 diabetes and weight loss, for treating obstructive sleep apnea (OSA) in obese adults. Developed by Eli Lilly, this drug offers an alternative to traditional breathing devices, addressing both obesity and sleep apnea. Long-term monitoring is advised.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/U7VKIqr
via IFTTT

Read More

NATHEALTH asks govt to address systemic gaps in healthcare in upcoming Budget

Union Budget: NATHEALTH urges the Indian government to address healthcare gaps like the shortage of medical specialists, rising cancer care costs, and inadequate hospital infrastructure in the union Budget. Recommendations include increasing healthcare budget to over 2.5% of GDP, reducing treatment costs, expanding hospital capacity, and improving medical education.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aPXYzFo
via IFTTT

Read More

Karnataka HC stays action against drug units making Nutraceuticals

The Karnataka High Court has provided temporary relief to pharmaceutical companies by directing the government not to act against firms producing nutraceuticals in drug-licensed units until the next hearing. This follows the industry's challenge to Schedule M, which prohibits manufacturing non-drug products in drug facilities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9l8hecW
via IFTTT

Read More

AbbVie Healthcare India rejects wrongdoing allegations by the Department of Pharmaceuticals

AbbVie Healthcare India has denied accusations of unethical marketing by the Department of Pharmaceuticals, asserting their compliance with applicable laws. The DoP flagged AbbVie for breaching the Uniform Code for Pharmaceutical Marketing Practices by sponsoring luxurious trips for doctors, leading to a probe into the company's tax liabilities and potential professional repercussions for the involved healthcare practitioners.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OpUoHPa
via IFTTT

Read More

Biocon, Zentiva get EU approval for generic diabetes, weight management drug

Biocon Ltd and Zentiva have secured decentralised procedure approval in the EU for Liraglutide, a complex formulation used for diabetes and weight management. This approval targets the generic versions of Novo Nordisk's Victoza and Saxenda, authorising their use in multiple EU member states simultaneously.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pRT79gW
via IFTTT

Read More

AbbVie Healthcare under government lens for 'violations'

The department of pharmaceuticals (DoP) reprimanded AbbVie Healthcare India for unethical marketing practices involving over ₹1 crore spent on foreign vacations for 30 doctors under the guise of conferences in Monaco and Paris. The Central Board of Direct Taxes (CBDT) and National Medical Council are to evaluate the company's tax liability and take action against the healthcare professionals involved.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RJhxrCl
via IFTTT

Read More

US FDA restricts imports of some Viatris products made in India

The FDA has restricted the importation of 11 products from Viatris' Indian facility due to violations of federal requirements. With exceptions for four products facing shortages, Viatris is implementing a remediation plan and collaborating with third-party experts to address the issues. Communication with the FDA is ongoing during this process.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vzMTkDN
via IFTTT

Read More

Ontario Teachers’ buys into Omega Healthcare

Ontario Teachers' Pension Plan and Goldman Sachs Alternatives are co-leading a major investment in Omega Healthcare, a US-based healthcare management solutions provider. This deal values Omega at $1.8 billion, with Ontario Teachers' acquiring a majority stake from Everstone Capital. Omega, with 35,000 employees globally, specializes in revenue cycle management and aims to improve healthcare efficiency through technology.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1RAuCem
via IFTTT

Read More

New list of over the counter drugs soon

India is developing a framework for over-the-counter (OTC) drugs, potentially allowing some prescription medications to be sold in general stores. A sub-committee is reviewing international guidelines and considering amendments to the Drugs and Cosmetics Act to regulate OTC drug distribution, marketing, and consumption, aiming to improve access while preventing misuse.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2VTHIZP
via IFTTT

Read More

Ontario Teachers' Pension Plan in advanced talks to acquire majority stake in Omega Healthcare

Ontario Teachers' Pension Plan (OTPP) is in advanced discussions to acquire a majority stake in Omega Healthcare Management Services for $1.7-1.8 billion. OTPP plans to invest $700-800 million, potentially partnering with Goldman Sachs, who currently holds a significant stake. This move highlights the growing private equity interest in healthcare BPOs amidst rising healthcare costs and complex regulations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tg0fkzw
via IFTTT

Read More

Zydus Lifesciences gets USFDA nod for generic topical anaesthetic cream

Zydus Lifesciences got USFDA approval for a generic anesthetic cream. The cream combines Lidocaine and Prilocaine. It numbs skin for minor procedures. Production will happen at their Ahmedabad site. This cream already generates millions in US sales.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5OPhSiH
via IFTTT

Read More

NPPA ropes in patent office to decide on pleas for price cap exemption

India's drug pricing regulator, NPPA, is increasing scrutiny of pharmaceutical companies seeking price exemptions. The NPPA is collaborating with the Indian Patent Office to evaluate applications, including those from Intas Pharmaceuticals and Biological E, under DPCO, 2013. These companies claim their new drugs, developed through indigenous research and patented in India, qualify for a five-year exemption from price controls.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vRdLCut
via IFTTT

Read More

GIC buys a majority stake in hospital platform Asia Healthcare Holdings

GIC has increased its stake in Asia Healthcare Holdings (AHH) with a $150 million investment, bringing its total investment to $320 million and gaining majority ownership. AHH, incubated by TPG Growth, operates a network of single-specialty hospitals in South Asia focusing on oncology, mother & childcare, urology & nephrology, and IVF & fertility.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CP0nLeT
via IFTTT

Read More

Quadria Capital to pick up minority stake in drug company Aragen

Quadria Capital is set to acquire a 10% stake in Aragen Life Sciences for about $100 million, valuing the Indian CRDMO at $1.2 billion. The investment will fuel Aragen's expansion, including a new biologics facility, and potentially pave the way for a future IPO. This move underscores the growing interest in Indian CRDMOs amid global pharma supply chain shifts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vJmcLPV
via IFTTT

Read More

Granules India gets USFDA nod for generic drug

Granules Pharmaceuticals, Inc. secured USFDA approval for generic Lisdexamfetamine Dimesylate chewable tablets. The tablets treat ADHD in children and adults. They also treat binge eating disorder in adults. The drug is available in various strengths. This approval addresses drug shortages. Granules India's chairman emphasized their commitment to patient needs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uGsQtPk
via IFTTT

Read More

Indian Pharma and healthcare sectors are poised for long-term growth: Centrum

India is set to strengthen its pharmaceutical and healthcare sectors. The government is launching production-linked incentives and building bulk drug parks. These initiatives aim to boost domestic drug production. The government is also promoting research and innovation in pharmaceuticals and medical technology. Support for traditional medicine (AYUSH) is also increasing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/c60RWnG
via IFTTT

Read More

SPARC enters pact with UCSF and Tiller Therapeutics for early stage oncology asset

Sun Pharma Advanced Research Company (SPARC) partners with Tiller Therapeutics. SPARC licenses its rights to a promising cancer treatment. The deal involves a pre-clinical oncology asset. SPARC gets a 55% equity stake in Tiller. This stake vests in two parts. The deal may lead to new treatments for solid tumors. SPARC shares saw a slight dip on Tuesday.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Zzm5qad
via IFTTT

Read More

Pharma lobby, govt meet to discuss OTC drug regulation

The drug regulator had earlier this year formed an expert panel to evaluate medicines which can become OTC from prescription after pharmaceutical companies approached the regulator to make their drugs OTC, a person said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1Zjv2JT
via IFTTT

Read More

Bavarian Nordic inks Mpox vaccine deal with Serum Institute

Bavarian Nordic A/S partnered with the Serum Institute of India to produce its mpox vaccine. The Serum Institute will supply the Indian market and expand Bavarian's global manufacturing capacity through a profit-sharing agreement. This comes as mpox cases surge, predominantly in the Democratic Republic of Congo, with a mutated strain spreading globally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lXZBWJw
via IFTTT

Read More

Zydus Lifesciences acquires 6.5 pc in Mylab Discovery Solutions for Rs 106 cr

Zydus Lifesciences invested Rs 106 crore in Mylab Discovery. Mylab is an Indian biotech company known for its diagnostic kits. They developed India's first COVID-19 testing kit. The deal gives Zydus a 6.5% stake in the company. Mylab notably developed a rapid COVID-19 test. The transaction is expected to close within two weeks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2lD48Sj
via IFTTT

Read More

Waiting time for orthopaedic surgeries increases at AIIMS, Delhi

Waiting times for orthopedic surgeries at AIIMS, Delhi have doubled to 12 months due to limited operating room functionality. Only four or five of the seven OTs are operational because of anesthesiology staffing shortages, impacting around 10 surgeries daily. This has prompted concerns from orthopedic surgeons, especially given the recent Rs 20 crore OT renovation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/z5TZ9hL
via IFTTT

Read More

Amid pollution woes, Asthma drug demand drives pharma retail market growth in November

India's pharmaceutical retail market rebounded in November with double-digit growth, fueled by increased demand for dermatological, cardiac, and respiratory medications. Foracort led sales, followed by Augmentin and Glycomet GP. Sun Pharma maintained market leadership. Analysts predict continued growth, boosted by new product launches, including anticipated generic GLP-1 drugs in 2025.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3fIKUNQ
via IFTTT

Read More

New panel to push Johnson & Johnson to look for more victims of 'faulty hip implant'

A government committee is working to compensate patients affected by faulty Johnson & Johnson hip implants. The committee aims to locate more patients eligible for compensation through advertising and will soon evaluate claims. J&J has paid 246 patients, but disputes the government's proposed compensation formula, preferring a lower amount.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pebiRO8
via IFTTT

Read More

J&J hip implant victims may soon get compensation

A newly reconstituted committee will likely soon begin evaluating compensation for patients affected by faulty hip implants sold by Johnson & Johnson. The government had previously accepted a formula offering up to ₹1.2 crore in compensation, but J&J disputed this and offered only ₹25 lakh. The case's final arguments are scheduled for December 18th in the Delhi High Court.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/w3mXjk9
via IFTTT

Read More

Cipla gets CDSCO nod to launch inhalation insulin

Cipla received approval from CDSCO to distribute and market Afrezza, an inhalable insulin, in India. Developed by MannKind, Afrezza offers a non-injectable alternative for adults with type 1 and type 2 diabetes. It begins working within 12 minutes, mimicking the body's natural insulin response. Cipla aims to improve diabetes management accessibility across India with this partnership.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tTCKkWf
via IFTTT

Read More

Reliance Strategic Business Ventures’ Rs 202 cr plan for Karkinos Healthcare approved by NCLT

The National Company Law Tribunal (NCLT) in Mumbai has approved Reliance Strategic Business Ventures Limited's Rs 202 crore resolution plan for Karkinos Healthcare Pvt. Ltd. (KHPL), which was undergoing insolvency proceedings. The plan, approved on December 9, 2024, ensures 100% recovery for all creditor classes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/W1uxA7P
via IFTTT

Read More

Govt prescribes faster access to medicines for rare diseases

India is streamlining access to rare disease drugs by waiving local clinical trials for some medications. The drug regulator is expediting approvals, facilitating imports, and prioritizing testing to ensure faster availability for patients. This includes fast-tracking global trial approvals and waiving trials for certain advanced therapies and drugs used in pandemics or for defence.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yX4wMpD
via IFTTT

Read More

Dr Morepen forays into wellness segment with weight management initiative

Dr. Morepen launched a new weight management program, LightLife, to combat India's rising obesity rates. The program uses scientifically-backed ingredients and a holistic approach including personalized nutrition plans and exercise guidance. The company aims to generate Rs 30 crore in revenue during the first year of the program's launch.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/BsyKaZ7
via IFTTT

Read More

Popular US-based weight loss drug maker Eli Lilly plans to launch medicine in India next year

Eli Lilly will launch Mounjaro in India in 2025. The drug treats type 2 diabetes and obesity. Lilly received marketing authorization in July. It is working on additional approvals. Mounjaro's global sales exceeded $3.1 billion in Q3 2024. Lilly will expand its diabetes portfolio in India with this launch. It has partnerships with Lupin and Cipla for other diabetes products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sPLpKV0
via IFTTT

Read More

Suven Pharma to acquire 56 pc stake in US-based firm for USD 64.4 mn

Suven Pharmaceuticals will acquire a 56% stake in US-based NJ Bio Inc for USD 64.4 million. This acquisition aligns with Suven's goal of becoming a leading technology-driven CDMO, specializing in antibody-drug conjugates (ADCs). NJ Bio's expertise and client base will boost Suven's presence in the rapidly expanding ADC/XDC market.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gyMqW8Y
via IFTTT

Read More

Laurus Labs biotech unit raises Rs 120 crore from Eight Roads Ventures

Laurus Bio has secured ₹120 crore in equity investment from Eight Roads Ventures and F-Prime Capital, with Laurus Labs co-investing ₹40 crore. This funding will expand Laurus Bio's fermentation-based manufacturing to meet growing demand for its animal-free proteins and growth factors used in various industries.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Upxzye2
via IFTTT

Read More

A comprehensive approach to diabetes care

India faces a significant diabetes challenge, with high prevalence, underdiagnosis, and poor control contributing to early complications and cardiovascular risks. Aggressive screening, lifestyle changes, and individualized treatment plans are crucial for effective diabetes management and improved health outcomes.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oJYurs2
via IFTTT

Read More

Dr Reddy's unit gets penalty of Rs 28.7 lakh from Kazakhstan authority

Dr. Reddy's Laboratories' Kazakhstan subsidiary has been fined Rs 28.7 lakh (KZT 17,597,212) by the Kazakhstani tax authorities. The penalty is for disallowed expenses claimed in 2021. Dr. Reddy's stated the penalty will not materially impact its financials or operations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/U1S2V5e
via IFTTT

Read More

Aurobindo unit gets USFDA nod for generic cancer drug

Aurobindo Pharma's subsidiary, Eugia Pharma, gets USFDA nod for cancer drug Pazopanib. The drug treats renal cell carcinoma and soft tissue sarcoma. Launch expected in Q4FY25. The market size is estimated at USD 106 million. Aurobindo's shares closed slightly lower on Thursday. The drug is a generic version of Novartis's Votrient.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AgyuYNZ
via IFTTT

Read More

Foreign investors in love with Indian hospitals, write $1.5 billion cheque

India's healthcare sector is booming. Hospitals now get the most foreign investment. This share has doubled since FY21. Investors are eyeing hospitals like Manipal and Max. The sector is growing due to market size and insurance coverage. Listed hospital chains plan to increase bed capacity by 47%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/G3jpoug
via IFTTT

Read More

Nearly 3,000 drugs failed quality test in FY24; 282 were spurious

In 2023-24, Indian authorities tested 106,150 drug samples, finding 2,988 substandard and 282 spurious. 604 prosecutions were launched against manufacturers and distributors. Risk-based inspections of over 500 pharmaceutical companies led to show-cause notices, production halts, and license suspensions or cancellations for non-compliance.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/YJSdHFW
via IFTTT

Read More

Kotak Pre-IPO fund to buy into diagnostic chain Neuberg

Kotak Pre IPO Opportunities Fund is in advanced talks to acquire a 15% stake in Neuberg Diagnostics for approximately Rs 450 crore. Neuberg's chairman, GSK Velu, plans to use the funds for acquisitions and expansion before a potential IPO next year. The diagnostics chain operates in multiple countries and processes millions of patient samples annually.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Y9M2Hcw
via IFTTT

Read More

Carlyle Group sells 4.3% in Indegene for ₹636 cr

Global investment firm Carlyle Group divested a 4.3% stake in Indegene for ₹636 crore via open market transactions, reducing its holding to 10.22%. Capital Group also sold a 2.24% stake in Medi Assist Healthcare Services for nearly ₹93 crore, trimming its holding to 0.7%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GlQHskh
via IFTTT

Read More

Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms

Novo Nordisk's team in India is urging the company to launch its popular weight-loss drug, Wegovy, next year to stay ahead of rival Eli Lilly. Concerns have been raised about Novo potentially lagging behind if Wegovy is not introduced before Lilly's drug, Mounjaro, in the Indian market where demand is high.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ikUSv43
via IFTTT

Read More

Parents challenge Covid vaccine safety in Supreme Court, cite adverse effects

Parents of children who died following Covid-19 vaccinations have filed a new affidavit in the Supreme Court, citing recent studies that highlight the "poor safety" of the vaccines and an increase in mortality rates post-vaccination. The affidavit includes testimonies from 40 individuals who either died or suffered severe adverse effects after receiving the vaccine.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Rj9OLmz
via IFTTT

Read More

Flipkart Minutes eyes 10-min drug delivery to outpace its rivals

Flipkart is preparing to launch a rapid delivery service named Flipkart Minutes, targeting medicine deliveries within 10 minutes. The service will use local chemists in metro areas for inventory, complying with India's drug regulations. This quick commerce initiative aims to tap into the largely unexplored market of medical deliveries, promising better margins than food and groceries.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Z3lxawe
via IFTTT

Read More

Milestone for India: Indigenous E-beam technology sterilises 50 lakh medical devices

Indore's electron beam radiation technology sterilized 50 lakh medical devices. This milestone was achieved by a premier institute of the Department of Atomic Energy. The facility started in October 2022 and has made India a part of the select group of countries using advanced radiation technology. The technology has diverse applications including medical device sterilization and more.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SRn5c61
via IFTTT

Read More

Reliance Industries-powered Strand Life Sciences unveils CancerSpot test for early detection of multiple cancers

Strand Life Sciences, a subsidiary of Reliance Industries, has introduced CancerSpot, a blood-based test for early cancer detection. It employs methylation profiling technology to identify tumor DNA fragments from blood samples. The test is tailored using data from Indian cohorts, making it relevant globally. This initiative aligns with Reliance's goal of advancing healthcare through genomics.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/AKzWTGJ
via IFTTT

Read More

Internet searches on mental health increased 41% this year: Report

Internet searches related to mental health in India surged by 41% in the first 10 months of this year compared to 2023, showing increasing recognition of mental wellbeing. Healthcare searches overall rose by 23%, with notable growth in non-metropolitan cities. Significant increases were seen in searches for psychologists, orthopaedic care, gynaecologists, and Ayurvedic doctors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/sW894F3
via IFTTT

Read More

Biocon Biologics gets US nod to launch Stelara biosimilar

Biocon Biologics has secured USFDA approval to launch the biosimilar of Janssen's Stelara by February 2025, targeting autoimmune conditions like Crohn's disease and plaque psoriasis. Despite competition from five other biosimilars, this launch is anticipated to significantly boost Biocon’s revenue and profitability.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/l0cAdEu
via IFTTT

Read More

Want a slimmer face? Try these 7 easy exercises

Want to slim down your face naturally? These 7 simple face exercises can help tone muscles, reduce fat, and give you a more defined look—no equipment needed!

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vJM3uDq
via IFTTT

Read More

Ficci seeks govt nod to restart import of pre-owned expensive medical equipment

Industry chamber Ficci has urged the government to permit the import of pre-owned and refurbished high-end medical equipment. Previously facilitated with a no objection certificate, such imports have stalled since August 15 due to new registration requirements with the Central Drugs Standard Control Organization (CDSCO), which currently lacks provisions for refurbished equipment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LHevXy8
via IFTTT

Read More

Devi Shetty sets his heart on UK’s Spire Healthcare

Narayana Health, led by Devi Shetty, is in advanced talks to acquire a controlling stake in Spire Healthcare Group amid a surge in the UK’s private healthcare demand. The Indian medical group aims to secure a 51-75% stake, potentially taking the company private, leveraging positive shareholder sentiments and global financing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/G5Xv8fu
via IFTTT

Read More

Suraksha Diagnostic is doing well, peers doing even better

Kolkata-based Suraksha Diagnostic is launching an offer for sale worth ₹846 crore, giving partial exit to OrbiMed Asia and reducing promoter holding. The company operates primarily in West Bengal and plans to expand its services and markets. The IPO values it at 73.5 times its annualized FY25 earnings.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/tSXe6JL
via IFTTT

Read More

Charitable hospitals to cover ESIC beneficiaries

Employees' State Insurance Corporation (ESIC) beneficiaries gain access to quality healthcare through the convergence with Ayushman Bharat-Pradhan Mantri Jan Arogya Yojana (AB-PMJAY). The initiative includes charitable hospitals and offers comprehensive care with no financial cap on treatment costs, benefiting over 14.43 crore ESI beneficiaries nationwide.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EztDwo3
via IFTTT

Read More

Dr Reddy's launches drug for neck, head cancer

Dr Reddy's Laboratories launched toripalimab, an immune oncology drug for adults with a rare form of head and neck cancer, in India. This drug is for treating recurrent or metastatic nasopharyngeal carcinoma. It will be marketed under the name Zytorvi. Before this, the standard treatment was chemotherapy with gemcitabine and cisplatin.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yE9ZaTP
via IFTTT

Read More

Why Japanese people don't get fat: 6 key lifestyle habits

Japanese people are known for their slim physiques and long lifespans. Their secret lies in a combination of healthy eating habits, portion control, and an active lifestyle. Here's why they rarely struggle with weight gain.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZgDjm0z
via IFTTT

Read More

Why you should be extra careful while taking Vitamin D; Doctors warn of severe complications like Kidney disease

Doctors warn against large vitamin D injections. They can harm bones and cause kidney stones. Monthly supplements are safer. Sunlight is the best source. Indians need more sun due to higher melanin levels. Pollution reduces sunlight's effectiveness. Eat vitamin D rich foods like fish and eggs. Office workers and those with certain health conditions are at risk of deficiency.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/pndYSk0
via IFTTT

Read More

Dr Reddy's launches immuno-oncology drug Toripalimab in India for treating nasopharyngeal carcinoma

Dr. Reddy's Laboratories launched Zytorvi (Toripalimab), a novel immunotherapy drug for recurrent or metastatic nasopharyngeal carcinoma (NPC), a rare head and neck cancer. This marks India as the third country globally with access to this next-gen PD-1 inhibitor, offering a superior treatment alternative to standard chemotherapy. Dr.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8MyPe7D
via IFTTT

Read More

Healthy ambitions: LIC eyeing ManipalCigna

LIC plans to buy half of ManipalCigna Health Insurance. The deal could be worth ₹4,000 crore. This move will let LIC enter the health insurance market. ManipalCigna is a joint venture between Manipal Group and Cigna Corporation. Both will reduce their stakes if the deal happens. LIC's managing director hinted at this acquisition during an earnings call.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5SVLJZq
via IFTTT

Read More

Abbott launches 14-valent pneumococcal vaccine for children in India

Abbott India launched PneumoShield 14, a pneumonia vaccine for children aged six weeks and older. This vaccine offers broader protection than existing vaccines by covering 14 pneumococcal strains, addressing infections like pneumonia and meningitis.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/KIktm5A
via IFTTT

Read More

Verlinvest leads race for minority stake in Eye Foundation

Verlinvest is poised to acquire a 20% stake in Eye Foundation for approximately $100 million, valuing the Indian eye hospital chain at Rs. 3,370 crore. This investment surpasses bids from other prominent investors and expands Verlinvest's growing healthcare portfolio in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8wmGtx2
via IFTTT

Read More

Zydus eyes M&A, licensing to build its US specialty business

Zydus Lifesciences is exploring mergers, acquisitions, and licensing to bolster its specialty portfolio in the US, particularly for the potential launch of its liver therapy drug. The company also aims to expand into medical devices, diagnostics, and nutrition businesses, focusing on profitable growth and a discovery-led approach by 2030.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4uIzoeQ
via IFTTT

Read More

Chickpea water benefits: How to make and use it for weight loss

Discover the wellness potential of aquafaba, commonly known as chickpea water, a versatile, nutrient-rich ingredient perfect for weight loss and healthy living.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DGp5vwf
via IFTTT

Read More

AstraZeneca Pharma gets CSDCO nod to import anti-cancer drug Lynparza

AstraZeneca Pharma India has received regulatory approval to import and distribute Lynparza (Olaparib) tablets in 100mg and 150mg doses. This approval allows the company to launch Lynparza in India for the maintenance treatment of advanced or recurrent endometrial cancer in adults who have not progressed following first-line treatment with Durvalumab and platinum-based chemotherapy, pending further approvals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/podM0AV
via IFTTT

Read More

SC to start hearing Covid-19 vaccine adverse effects case

The Supreme Court is hearing a case where two parents allege their daughters died from Covishield vaccine side effects. The government maintains the vaccination program was voluntary and safe, citing billions of doses administered. The parents argue the government misrepresented the vaccine's safety and seek compensation and an independent investigation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FfsqNRH
via IFTTT

Read More

Lupin recalls over 6 lakh bottles of hypertension drug in US: USFDA

Lupin Pharmaceuticals is recalling over 600,000 bottles of Ramipril blood pressure medication in the US due to an unapproved ingredient supplier. Dr. Reddy's Laboratories is also recalling 3,416 bottles of ibuprofen tablets due to failed specifications. Both recalls are voluntary, with Lupin's classified as Class II (temporary or reversible health consequences) and Dr.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/j8Opfxh
via IFTTT

Read More

Healthcare access for all Indians by 2047: AI and health data have roles to play

India aims for universal healthcare access by 2047. A new report proposes a tiered system. This system uses data and AI. It categorizes the population by income. The goal is to improve government schemes and insurance. India needs more healthcare investment. The current system is costly and inefficient. Claim sizes and medical inflation are rising. Reforms are urgently needed.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cHnlV1s
via IFTTT

Read More

India's pharma sector registers strong Q2 FY25 growth, driven by North America market: Report

The major pharmaceutical companies of the country reported a 10 per cent year-on-year (YoY) growth in the second quarter of FY25, largely driven by strong performance in North America and the domestic market, according to a report by Axis Securities.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/CGPNY4X
via IFTTT

Read More

Universal Health Coverage: Community health workers ‘the missing link’ say experts

Healthcare experts in Bengaluru are advocating for a strengthened community healthcare system in India to combat the rise of non-communicable diseases and achieve Universal Health Coverage. They propose training a dedicated cadre of community health workers to provide consistent monitoring and leverage technology for data collection and telemedicine, bridging gaps in existing programs like Ayushman Bharat.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9UYGydP
via IFTTT

Read More

Aurobindo joins hands with global pharma player to develop respiratory products

Aurobindo Pharma's US subsidiary has partnered with a global pharmaceutical company to develop and sell respiratory products. The collaboration involves a shared cost of up to $90 million over three to five years, with both companies sharing marketing rights while the unnamed partner handles manufacturing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Bc7DHkV
via IFTTT

Read More

John Hopkins University and Ajit Isaac Foundation to establish 63-bed Palliative Care Centre in Tumkur

Johns Hopkins University and the Ajit Isaac Foundation partnered to establish palliative care centers in underserved areas of India. The collaboration will focus on training caregivers, developing curriculum, and offering mentorship to improve end-of-life care for terminally ill patients.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/4DPi9tI
via IFTTT

Read More

Festivity and diabetes: a guide to healthy indulgences and guilt-free joy!

Diwali and the Indian wedding season, while joyous, pose a challenge for managing diabetes due to the abundance of sweets. High sugar intake during these celebrations can lead to health complications, especially for India's large diabetic population. The article provides tips for a healthy festive season, including choosing healthier alternatives, portion control, staying active, and monitoring blood sugar levels.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/UwfkqxH
via IFTTT

Read More

360 ONE Asset acquires stake in OneSource Specialty Pharma

360 ONE Asset has acquired a stake in OneSource Specialty Pharma, a Contract Development and Manufacturing Organization (CDMO), for an undisclosed amount. The investment will support OneSource's innovation and global expansion plans. OneSource recently raised $95 million from other investors and is preparing to list its shares on stock exchanges.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QHh09nE
via IFTTT

Read More

How long sitting hours harm your health and how to avoid it

Incorporating movement and ergonomic adjustments into your routine can counteract the harmful effects of sitting. Small, consistent changes can significantly improve your overall well-being.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rRe9Hq8
via IFTTT

Read More

About 18% of deaths in 2019 attributable to air pollution: ICMR study

A report by India's leading health research body found that air pollution caused 1.7 million deaths in 2019. This represents 18% of all deaths in the country that year. The primary cause of death was chronic obstructive pulmonary disease (COPD). The study identified industrial emissions, vehicular exhaust, and the burning of solid fuels as major contributors to air pollution.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/6uS1Cwy
via IFTTT

Read More

Project SPECS of WHO will soon be implemented in Assam

The World Health Organization (WHO) is partnering with Sri Sankaradeva Nethralaya (SSDN) to launch the SPECS project in Assam, India. This pilot program aims to provide comprehensive eye care services, focusing on refractive errors, in three districts. The initiative will leverage SSDN's community-based approach and serve as a model for WHO's global efforts to improve eye health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fSTY5bm
via IFTTT

Read More

Wockhardt chairman seeks GST exemption for antibiotics discovered in India

Wockhardt founder sought GST exemption for antibiotics discovered in India. He said this will make the drugs more affordable. The statement was made at an event to celebrate the scientific completion of the first indigenously developed antibiotic Nafithromycin. Nafithromycin is the first macrolide antibiotic in 30 years for community-acquired bacterial pneumonia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/l5WrHTC
via IFTTT

Read More

High pollution may boost demand for respiratory drugs

"The respiratory market shows the normal seasonal trend for the anti-asthma and cough and cold segment," said Sheetal Sapale, VP, commercial, Pharmarack. "There were fewer reported cases in October 2024 compared to October 2023, hence there is de-growth in the market. The market peaks in December and January and then gradually subsides as winter loses its intensity," Sapale said.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qt0vgsj
via IFTTT

Read More

Covid shots: Parents seek vaccine courts to ensure 'swift' justice

Parents of children who allegedly died from COVID-19 vaccine side effects are demanding justice and transparency in public health policies. They are calling for faster legal proceedings and a revamped system for reporting adverse events following immunization.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3HOrCEA
via IFTTT

Read More

Tired eyes? Try these 7 yoga poses for better vision naturally

These yoga asanas can help relax the eyes, strengthen eye muscles, and improve vision naturally. Regular practice, combined with a healthy lifestyle, can yield lasting benefits.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/iUm4y0A
via IFTTT

Read More

Glenmark to focus on becoming branded company, says Glenn Saldanha

Glenmark Pharmaceuticals, having navigated recent challenges, is shifting its focus to branded products for higher profit margins. The company, aiming for a 12%-15% growth rate, divested its active pharmaceutical ingredient business to concentrate on branded pharmaceuticals, particularly in respiratory, dermatology, and oncology.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FkqJe5o
via IFTTT

Read More

Biocon Biologics looks to trim $300 million debt in 1 year

Biocon Biologics plans to reduce its acquisition debt by $300 million over the next year. The company recently refinanced $1.1 billion in debt, providing more financial flexibility. Biocon aims to capitalize on the growing insulin market, with plans to double its insulin production capacity in Malaysia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VUW7gHT
via IFTTT

Read More

Supreme Court asks Zydus Lifesciences to approach Delhi HC over ban on selling breast cancer drug Sigrima

The Supreme Court has instructed Zydus Lifesciences to approach the Delhi High Court. Zydus is seeking relief from an order that prevents the sale of its breast cancer drug, Sigrima. Swiss pharmaceutical giant, Roche, alleges that Sigrima is similar to its own cancer drug. Roche requested the court to prohibit Zydus from selling Sigrima.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bCA6GZF
via IFTTT

Read More

Morning walks in high pollution: Safe or risky? How to stay active safely

While morning walks are often associated with numerous health benefits, they may not be safe during periods of high air pollution. By adapting your routine and staying informed about air quality, you can maintain an active lifestyle without risking your well-being.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZhMrECV
via IFTTT

Read More

Dr Reddy's, FDC recall products in US for manufacturing issues

Dr Reddy's Laboratories and FDC Ltd issued voluntary recalls for medications in the US market due to manufacturing defects. Dr Reddy's recalled lots of Morphine Sulfate extended-release tablets due to failed impurity specifications, while FDC Ltd recalled Timolol Maleate ophthalmic solution due to defective containers hindering solution dispensing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vgHbkZK
via IFTTT

Read More

Menopause is hot: How celebrities and startups are transforming women's health

Menopause is having a moment, with celebrities and entrepreneurs capitalizing on the growing global market for menopause-related products and services. Indian women are also seeking solutions, leading to a surge in femtech startups offering everything from supplements and digital platforms to community support, aiming to break the taboo surrounding menopause.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/10N7xs9
via IFTTT

Read More

Telangana secures over Rs 36,000 crore in life sciences investments, genome valley leads the way

Telangana's Genome Valley is attracting substantial investments in life sciences. Over Rs. 36,000 crore was invested in the past year. This resulted in over 140 new projects. These projects include pharmaceutical manufacturing, R&D centers, and vaccine production. International companies are partnering with Indian businesses. The government expects these investments to create thousands of jobs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2OPGcH5
via IFTTT

Read More

6 health benefits of drinking black coffee without sugar every day

Black coffee is a simple, calorie-free beverage with numerous health advantages. By skipping sugar, it becomes a powerhouse of nutrients and compounds that promote overall wellness. Here are six key benefits of drinking black coffee without sugar:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XEmecAI
via IFTTT

Read More

Diabetes too serious to be left to medical professionals only: Jitendra Singh

India is tackling its diabetes epidemic head-on. At the 52nd Annual Conference of the Research Society for the Study of Diabetes in India, experts stressed the need for public-private partnerships to address the disease affecting over 10 crore Indians.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5lqofW8
via IFTTT

Read More

7 surprising ways to use tea beyond drinking you didn't know about

Discover 7 surprising ways to use tea beyond just drinking! From reducing puffy eyes and fighting dandruff to deodorizing your home and repelling pests, these creative tea hacks will transform your routine.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/S0XVsA3
via IFTTT

Read More

Want to add beetroot to your diet? Here are 7 healthy & colorful recipes for every meal

Beetroot is a nutrient-packed vegetable known for its rich color and health benefits. Here are seven delicious and healthy beetroot recipes to enjoy throughout the day.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/f9ZbEgi
via IFTTT

Read More

India has the highest number of diabetic people in the world, even more than China: Report

A new study reveals that over 800 million adults worldwide have diabetes. India leads the world with 212 million cases, followed by China with 148 million. The US has 42 million cases. The global diabetes rate has doubled since 1990. The study used data from over 140 million people across more than 1,000 studies.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/fbr1clT
via IFTTT

Read More

US-based AptarGroup breaks ground for new pharma plant in Taloja, near Mumbai

AptarGroup held a groundbreaking ceremony for a new pharmaceutical plant in Taloja, India. The facility expands AptarGroup's presence in the region. The plant will produce pressurized metered dose inhaler valves, breath-actuated devices, and single-dose nasal sprays. The company is exploring acquisitions to expand its drug delivery offerings.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FVuA4em
via IFTTT

Read More

Pharma market sees 6.1% growth in October despite subdued volumes

Amongst the top 10 therapies that contribute to more than 90% of the Indian pharma market, price drove growth in the cardiac segment. The anti-hypertensives, which account for almost 50% of the cardiac segment, is experiencing stagnated volume growth. Lipid-lowering drugs and platelet aggregation inhibitors have shown a relatively higher growth to help boost the cardiac segment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9gUHqbF
via IFTTT

Read More

Neem or curry leaves for healthier hair: Which works better?

Neem and curry leaves are popular natural ingredients for hair care, each offering unique benefits. Neem is known for its powerful antifungal and antibacterial properties, while curry leaves are rich in nutrients that strengthen and promote hair growth. Here’s a comparison to help you decide which might be better for your hair needs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uiPE9JK
via IFTTT

Read More

Diabetes and heart health: Acting early

Type 2 diabetes significantly elevates the risk of heart disease, making individuals more susceptible to heart attacks, strokes, and heart failure. Early management is crucial, focusing on blood sugar control, blood pressure and cholesterol management, weight loss, and lifestyle modifications. This proactive approach can provide long-term heart health benefits, known as the "legacy effect."

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ylBWEub
via IFTTT

Read More

Alembic Pharmaceuticals gets USFDA nod for generic hypertension treatment capsules

Alembic Pharmaceuticals Ltd has secured final approval from the USFDA for its generic Diltiazem Hydrochloride extended-release capsules. These capsules, available in strengths of 120 mg to 360 mg, are designed to treat hypertension and manage angina. This approval grants Alembic access to an estimated market valued at USD 105.3 million annually.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/yXOLMB6
via IFTTT

Read More

TA Associates to acquire majority stake in Vee Healthtek for $250 m

US private equity firm TA Associates is set to acquire a majority stake in Vee Healthtek, an Indian revenue cycle management firm, for $250 million. The deal marks TA's entry into India's RCM market and its second investment in the country's healthcare IT sector.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/R51ofd2
via IFTTT

Read More

Winter superfoods: 8 dry fruits and seeds to eat, their benefits, and ideal portions

Discover 8 dry fruits and seeds to boost your health this winter. Learn their benefits and the ideal servings for enhanced immunity, energy, and overall well-being.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/wKAbOS9
via IFTTT

Read More

Medical devices industry welcomes government's Rs 500-crore scheme

India's medical device industry is celebrating a new ₹500 crore government scheme designed to boost domestic manufacturing and reduce reliance on imports. The scheme will fund key initiatives such as manufacturing essential components, developing shared infrastructure, and supporting clinical studies, ultimately aiming to position India as a global leader in medical technology.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/twC7jDc
via IFTTT

Read More

Hashimoto's disease explained: Arjun Kapoor's battle, symptoms, and risks

Arjun Kapoor opens up about his struggle with Hashimoto’s disease, an autoimmune disorder affecting the thyroid. This slideshow explores the symptoms, risk factors, and what the condition entails for Kapoor.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/q15MALr
via IFTTT

Read More

Which weight loss method is most effective: Fasting, early eating, or fewer meals?

This research compares three popular weight-loss methods: intermittent fasting, eating earlier in the day, and consuming fewer meals. All methods show similar results, so choose the one that fits your lifestyle.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/FDoWMLq
via IFTTT

Read More

Labour Ministry enters into MoU with Cygnus Ujala to enhance employability in the healthcare sector

The Ministry of Labour and Employment has partnered with Cygnus Ujala to boost healthcare job opportunities on the National Career Service (NCS) portal. This collaboration aims to add 25 lakh vacancies, focusing on Tier II and Tier III cities, with an emphasis on women's employment.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ik1GdsX
via IFTTT

Read More

NPPA asks companies to cut prices of three cancer drugs post tax relief

In a move aimed at providing relief to cancer patients, the National Pharmaceutical Pricing Authority (NPPA) has directed drug manufacturers to reduce the maximum retail price (MRP) of three crucial cancer drugs. This directive follows the government's decision to exempt Trastuzumab Deruxtecan, Osimertinib, and Durvalumab from Customs duty and reduce GST rates on these medications.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7QJvgN8
via IFTTT

Read More

Medanta enters O&M for 750 bed super specialty hospital in New Delhi; to invest Rs 600 crore

Global Health, the company behind Medanta hospitals, has partnered with Dr. Narayan Dutt Shirmali Foundation to manage a new 750-bed super specialty hospital in Pitampura, New Delhi. The hospital, expected to open in four years, represents a Rs. 600 crore investment for Medanta and will offer a wide range of specialized medical services.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mX7YhRp
via IFTTT

Read More

OmniActive Health acquires botanical ingredients company ENovate Biolife

OmniActive Health Technologies, a Mumbai-based nutraceutical company, has acquired ENovate Biolife, a developer of botanical ingredients. This acquisition, funded through internal accruals, marks OmniActive's second strategic expansion. OmniActive aims to double its revenue to ₹2,000 crores within the next 5 to 6 years.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5NkcLRy
via IFTTT

Read More

Health groups raise concerns over patents for rare disease drugs

Health groups and patient advocates are raising concerns over patent monopolies on rare disease drugs in India. They argue that these monopolies, like the one held by Roche for the spinal muscular atrophy drug Risdiplam, restrict access to affordable medication.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/i1HIR4y
via IFTTT

Read More

Venus Remedies gets GMP approval for pre-filled syringe facility

Indian pharmaceutical company Venus Remedies received a significant approval from the Malaysian authorities. The company's Baddi facility, equipped with advanced robotic technology, met the stringent quality standards for producing pre-filled syringes. This recognition paves the way for Venus Remedies to expand its global presence and provide critical medications to more countries.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mJBNakw
via IFTTT

Read More

CDSCO may regulate health supplements to stem unapproved claims by firms

A government panel in India is proposing stricter regulations on health claims made by supplement manufacturers. The panel suggests shifting control from the food safety authority to the drug regulator, aiming to curb exaggerated claims related to disease treatment or risk reduction.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ichOSme
via IFTTT

Read More

US firm Alkomex to expand R&D footprint in India

Global pharmaceutical company Alkomex GBN is expanding its research and development operations into India. The company has appointed nutraceuticals expert Dr. Sanjay Agrawal as Scientific Advisor to lead these efforts. Based in Ahmedabad, Dr. Agrawal will oversee research and strategic initiatives, integrating Indian research into Alkomex's global operations.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O0euwlI
via IFTTT

Read More

FSSAI sets stricter rule for antibiotics in food items

"If enforced strictly, the regulations will ensure safer food products for consumers by setting stricter residue and contaminant limits across a variety of food items and help in dealing with antimicrobial resistance," said George Cheriyan, working president of Consumers Protection Association (CPA). The FSSAI has also prohibited the use of antibiotics during honey production and reset the limit of the chemicals ochratoxin A and deoxynivalenol in wheat, wheat bran, barley, rye and coffee.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Z6CwgT3
via IFTTT

Read More

Bajra roti or wheat roti? Which is better for health and weight loss?

Choosing bajra roti over wheat can be a great step toward better health and well-being. Here are the key benefits of choosing bajra roti over wheat for a healthier lifestyle.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/H0mS6M3
via IFTTT

Read More

Dr Reddy's recalls over 3.3 lakh bottles of generic medication in US: USFDA

Dr Reddy's Laboratories is recalling over 3.3 lakh bottles of Cinacalcet tablets in the US due to manufacturing issues. The recall is due to the presence of an impurity above FDA limits. The recall affects 30 mg, 60 mg, and 90 mg strengths, with the affected lot produced in India. The recall was initiated on October 9, 2023.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DIbUnKx
via IFTTT

Read More

Apollo Hospitals announces Rs 1,625 crore expansion in Mumbai and Lucknow

Apollo Hospitals announces a major expansion plan in Mumbai and Lucknow with a total investment of Rs 1625 crore over the next four years. The expansion, involving a 500-bed facility in Worli and a 200-bed extension in Lucknow, will be funded through internal accruals and debt financing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gVjTe08
via IFTTT

Read More

From fish to seeds: 5 excellent sources of Omega-3 fats for a healthier diet

Omega-3 fatty acids are essential fats that play a crucial role in maintaining heart health, supporting brain function, and reducing inflammation. While fatty fish are well-known sources, there are several other foods you can include in your diet to ensure you’re getting enough omega-3s. Here are five excellent sources to consider:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/7aJrhny
via IFTTT

Read More

Suven, Cohance aim to double combined business revenue to Rs 6,000 cr by FY29

Suven Pharmaceuticals and Cohance Lifesciences plan to merge and aim to double their revenue to Rs 6,000 crore by FY29 through organic and inorganic growth. The merger has received NSE and BSE approvals, with a shareholders meeting scheduled for November 28, 2024. The combined entity will focus on pharma CDMO, specialty chemicals CDMO, and APIs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ITczxfL
via IFTTT

Read More

Govt to recast Insacog as Covid cases decline

The Indian government is considering restructuring Insacog, the consortium monitoring genomic variations in SARS-CoV-2, due to the decline in new Covid-19 cases and reduced testing frequency. Experts aim to determine whether to continue extensive sequencing or streamline it to fewer laboratories based on current needs.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/GVuWKcm
via IFTTT

Read More

Yatharth Hospital to acquire 60% stake in Faridabad-based facility

Yatharth Hospital and Trauma Care Services has greenlit the acquisition of a 60% stake in a yet-to-be-operational 400-bed hospital in Faridabad valued at Rs 152 crore. This move, alongside acquiring a super speciality hospital in Model Town, Delhi, aims to bolster its presence in the Delhi-NCR region.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3utniv4
via IFTTT

Read More

SumeetSSG to invest Rs 1,600 cr in Maharashtra; bags emergency medical service project

Medical emergency service provider SumeetSSG will invest Rs 1,600 crore in Maharashtra to implement the MEMS 108 Ambulance Project, introducing advanced ambulance fleets with specialised medical equipment. The ten-year project, valued at Rs 14,000 crore, aims to enhance healthcare infrastructure and emergency response services across the state.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/982qPQt
via IFTTT

Read More

Biocon Biologics' Bengaluru unit classified as voluntary action indicated by USFDA

Biocon Biologics' drug substance facility in Bengaluru has been classified by the USFDA as voluntary action indicated after a cGMP inspection conducted in February 2024. The classification means that while some objections were noted, no regulatory action is recommended. The facility is responsible for supplying rh-Insulin drug substance to the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/A8l4LIK
via IFTTT

Read More

Cipla Q2 hit by seasonal chill, but investors need not worry

Cipla's September-quarter performance saw a 5.6% increase in consolidated net sales and a 15% rise in net profit despite slow seasonal growth in the anti-infectives category. The company expects a resurgence in growth due to seasonal respiratory illnesses and plans to address supply challenges and facility remediations in upcoming quarters.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uPDmSRM
via IFTTT

Read More

Fortis Healthcare gets CCI nod to acquire additional stake in Agilus Diagnostics for Rs 1,780 cr

The Competition Commission of India (CCI) has approved Fortis Healthcare's acquisition of an additional 31.52% stake in Agilus Diagnostics, raising its total share to 89.2%. Additionally, CCI has greenlit the merger of Diliigent Power into DB Power and the reorganisation of Decore Thermal Power.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bQkLmIr
via IFTTT

Read More

Lyfius Pharma Penicillin-G plant inaugurated by PM Modi

Prime Minister Narendra Modi virtually inaugurated Lyfius Pharma's Penicillin-G plant in Kakinada, Andhra Pradesh, with a production capacity of 15,000 MT. The Rs 2,500 crore investment under the PLI Scheme aims to boost domestic manufacturing, reduce import dependency, and support 'Atmanirbhar Bharat' in establishing India as a global pharmaceutical hub.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zJ14kOU
via IFTTT

Read More

Govt asks manufacturers to cut price of 3 anti-cancer drugs

The government has directed manufacturers to lower prices of Trastuzumab, Osimertinib, and Durvalumab after exempting them from customs duty and reducing GST. This measure aims to ensure affordable anti-cancer drugs for consumers. Companies must update and report new prices to authorities and dealers.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/L8xRb4u
via IFTTT

Read More

PM Modi to launch, inaugurate multiple health sector projects worth over Rs 12,850 cr today

On the occasion of Dhanvantari Jayanti and 9th Ayurveda Day, Prime Minister Narendra Modi will launch, inaugurate and lay the foundation stone of multiple projects related to the health sector worth around Rs 12,850 crore on Tuesday at the All India Institute of Ayurveda (AIIA) in the national capital.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9oFv5Ei
via IFTTT

Read More

Dr Reddy's launches medication to treat chronic constipation

Dr Reddy's Laboratories has launched BixiBat, a new drug for chronic constipation in India. It is the first company to receive approval from the CDSCO for Elobixibat. The drug works by increasing bile acid concentration in the colon, promoting bowel movements. Clinical studies showed promising results. Shares of the company went up by 0.84 percent.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bViqB0G
via IFTTT

Read More

NCIL developing indigenous dialysis machine in collaboration with NIT Silchar

Nephro Care India Limited, in collaboration with NIT, Silchar, is developing an AI-enabled smart haemodialysis machine with a grant from West Bengal's Department of Science and Technology. This prototype aims to slash costs by up to 75%, making renal care more affordable and accessible, especially in rural areas.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qiAbKfX
via IFTTT

Read More

Could a Rs 72 lakh drug cost just Rs 3,000? A 24-year-old's courtroom revelation

A 24-year-old SMA patient in Kerala High Court revealed that Risdiplam, a crucial SMA drug, could be locally produced for Rs 3,000 annually compared to the current Rs 72 lakh. Highlighting the need for local manufacturing, the petition challenges the sufficiency of the Indian Health Ministry's financial aid and crowdfunding efforts.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/x9huOws
via IFTTT

Read More

Piramal Pharma deploying USD 85 mn capex this fiscal: Nandini Piramal

Piramal Pharma is investing USD 85 million this fiscal for initiatives like capacity expansion and maintenance. They have already used USD 30 million in the first half. Part of the funds will be for domestic use and some for the US. The company aims to reach USD 2 billion in revenue by FY30.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ySeLq6I
via IFTTT

Read More

Big chase for a cancer drug: The urgent need for affordable Keytruda alternatives

Keytruda, a cancer treatment drug, has achieved $25 billion in global sales. Its mechanism boosts the immune system to fight cancer. In India, its high cost limits access. With patents expiring soon, Indian companies are developing more affordable versions. Efforts are also focused on expanding indications and improving financial access.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Qq2VPOL
via IFTTT

Read More

Abhay HealthTech acquires MNP Healthcare to expand footprint in OTC segment

Abhay HealthTech has acquired MNP Healthcare to expand its OTC consumer healthcare sector. The deal includes MNP's brands, products, people, and manufacturing facilities. MNP Healthcare's directors will join Abhay HealthTech's advisory board. This acquisition enhances Abhay HealthTech's portfolio in areas like rapid testing kits, hygiene, skincare, supplements, women and baby care, and children wellness.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ArwHT2D
via IFTTT

Read More

Calcium, Vitamin D3 tablets, 47 others fail CDSCO's quality check: Check if your medication is safe?

The Central Drugs Standard Control Organisation (CDSCO) identified 49 drugs failing quality tests in its September report. Among these are commonly prescribed antibiotics, supplements, and pain relievers. The report also flagged four products, including popular calcium and prostate treatments, as “spurious,” manufactured by unverified companies. CDSCO’s ongoing efforts, which involved sampling 3,000 drug batches in September alone, are aimed at minimizing non-standard drugs in the market, ensuring the safety of public health through rigorous monthly monitoring.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/e8En12y
via IFTTT

Read More

Why technology alone can't fix India’s big healthcare divide

India's healthcare gap can't be bridged by technology alone; infrastructure and human resources are essential. Rural areas face severe deficiencies in medical facilities and professionals. Affordability and awareness also present major challenges, requiring comprehensive investment and public health campaigns to address these deep-rooted issues.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/EHO6oPx
via IFTTT

Read More

Want glowing skin? Include these 5 drinks in your diet

Get a radiant, healthy glow by adding these five skin-loving drinks to your daily routine. From green tea to beet juice, each boosts hydration and revitalizes skin.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/lT5mbIt
via IFTTT

Read More

Pharma bodies flag risks of refurbished medical gear imports

Medical device manufacturers are urging India's health minister to revoke the policy allowing unchecked import of refurbished medical devices like CT scanners and MRI machines. They argue this poses risks to patient safety and jeopardizes investments made under the Make in India initiative. They seek stricter regulations to ensure compliance with the National Medical Devices Policy 2023.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5DHFV8I
via IFTTT

Read More

Weight-loss drugs didn't curb health costs within two years, data show

U.S. health insurance claims analysis shows that two years after starting Novo Nordisk's Wegovy or similar GLP-1 drugs, annual medical costs for obese patients increased by 46% to $18,507, with no reduction in obesity-related medical events compared to a control group. These high costs concern employers and government officials.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9WsZrNp
via IFTTT

Read More

Mankind Pharma completes Rs 13,768 cr BSV acquisition

Mankind Pharma has completed the acquisition of Bharat Serums and Vaccines Ltd for Rs 13,768 crore. This acquisition strengthens Mankind Pharma's position in the Indian women's health and fertility drug market. The transaction aligns with Mankind's strategy to access high entry barrier products and complex R&D platforms, promising accelerated growth and expanded market access.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8TzXQpi
via IFTTT

Read More

McDonald's E. Coli outbreak: Symptoms, source, and when to get medical help

An E. coli outbreak linked to McDonald's Quarter Pounders has left one person dead and 49 others ill. Find out its symptoms, likely sources of contamination, and when to seek medical help.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/QI19TLX
via IFTTT

Read More

Zydus Lifesciences gets WHO prequalification for Typhoid Vi conjugate vaccine

Zydus Lifesciences Ltd has received in-principle approval from the WHO for its Typhoid Vi conjugate vaccine, ZyVac TCV. Eligible for UN procurement, the vaccine targets 6-month to 65-year-olds and addresses high typhoid incidence in India, Africa, and Southeast Asia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LPqGtRs
via IFTTT

Read More

GST reduction will make insurance little affordable for customers, says Department of Finance Joint Secy

The Department of Finance's Joint Secretary stated that a reduction in Goods and Services Tax (GST) could make insurance more affordable for customers. Following requests for the removal of GST on term life and health insurance premiums, a Group of Ministers (GoM) met to discuss potential exemptions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ybhCFUe
via IFTTT

Read More

Manipal HealthMap acquires iGenetic Diagnostics

Manipal HealthMap has fully acquired Mumbai-based iGenetic Diagnostics to enhance its diagnostic services in key markets such as Maharashtra, Madhya Pradesh, and Karnataka. The acquisition aims to establish over 200 centers by 2027, contributing to a more integrated diagnostic services network across India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/X6xgpTu
via IFTTT

Read More

8 eco-friendly tips to combat air pollution during Diwali

Diwali is a time of celebration, but it can also lead to increased air pollution. By adopting eco-friendly practices, we can enjoy the festivities while protecting our environment and health. Here are eight effective ways to combat air pollution this Diwali.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MKibS6Y
via IFTTT

Read More

Diabetes, cardiac drugs market grows over 3x in 10 years

India's cardiac and anti-diabetes drugs market has surged over threefold in the past decade, reaching ₹30,000 crore and ₹17,000 crore respectively. Innovative medicines and loss of patents have driven growth, with several brands now contributing significantly to market turnover.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/VGmJgX1
via IFTTT

Read More

The ‘A’ and ‘B’ of diabetes: When less is more

HbA1c testing is crucial for diabetes management as it reflects average blood sugar levels over three months, unlike single-point fasting or postprandial tests. Regular testing and weight management can significantly reduce diabetes complications, yet many people in India neglect this vital check, exacerbating health risks.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5vKZ3M2
via IFTTT

Read More

Alembic Pharma gets USFDA nod for generic hypertension treatment capsules

Alembic Pharmaceuticals has received USFDA final approval for its generic Diltiazem Hydrochloride extended-release capsules in strengths of 120 mg, 180 mg, and 240 mg to treat hypertension and chronic stable angina. These capsules are therapeutically equivalent to Allergan Sales LLC’s Dilacor XR, with an estimated market size of USD 28.2 million.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/LRUItQN
via IFTTT

Read More

Indian pharma firms trail global peers in R&D, innovation, and talent metrics: FAST India-IIFL Securities

Indian pharmaceutical firms lag behind global companies in R&D intensity, PhD employee proportion, and patents and publications per billion USD revenue, the report said. Global firms produce significantly more patents and publications, it added.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/gAqY2wJ
via IFTTT

Read More

India's bioeconomy valued at $150 bn, innovation holds key to global leadership: BIRAC MD

India's biotechnology sector, valued at USD 150 billion, is expanding, yet innovation and product development potential remain untapped. BIRAC supports startup growth and R&D investment to elevate India's bioeconomy, though increased private-sector investment and streamlined regulatory processes are essential for global leadership in biotech.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/5v48bkq
via IFTTT

Read More

GST on term life insurance premium, senior citizen's health coverage likely to be exempt

The Group of Ministers (GoM) is likely to recommend exempting Goods and Services Tax (GST) on term life insurance premiums and health insurance premiums paid by senior citizens. During a recent meeting, the GoM decided to exempt GST for health insurance coverage up to Rs 5 lakh for individuals (excluding seniors), while premiums above this threshold will still attract 18% GST. Currently, 18% GST applies to life insurance premiums as well.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/ZSewcEy
via IFTTT

Read More

7 common post-meal mistakes that can ruin your digestion

By being aware of these post-meal habits and making adjustments, you can support better digestion and enhance your overall health.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/zkXF35h
via IFTTT

Read More

Sparsh Hospitals lines up expansion plans

The Sparsh Group of Hospitals, led by Sharan Shivaraj Patil, plans to expand by investing ₹350-400 crore in two new Bengaluru hospitals and ₹150 crore in an R&D centre. They aim to raise equity funds in fiscal 2026. The company remains profitable and will add some debt for expansion.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/vCcwypE
via IFTTT

Read More

Stop believing these 6 nutritional myths: Get the facts!

Nutritional myths can often mislead us, making it difficult to make informed choices about our diets. Here are seven common nutritional myths that you should stop believing:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Q1sN9BJ
via IFTTT

Read More

Alia Bhatt opens up about ADHD: Key insights & symptoms you should know

Alia Bhatt opens up about her ADHD journey, sharing how it affects her daily life and moments of peace. She discusses her diagnosis, common symptoms, and how it shapes her experiences on set and with her daughter.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0th9LrM
via IFTTT

Read More

NCLAT closes insolvency proceedings against JHL as Max Healthcare settles creditor's claims

The National Company Law Appellate Tribunal (NCLAT) has ended insolvency proceedings against Jaypee Healthcare, as financial creditors' dues were settled by Max Healthcare with a Rs 1,035.29 crore payment. The CIRP was initiated by NCLT following a petition by JC Flowers Asset Reconstruction Ltd.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3MacBfH
via IFTTT

Read More

Pleasure profits: Sex stimulants show enhanced performance

Sales of sex stimulants and rejuvenators in India have surged by 17% over the past year, with significant gains in sildenafil and tadalafil brands like Viagra and Cialis. This growth is attributed to decreased inhibitions and increased openness to sexual wellness, supported by accessible knowledge and healthcare professionals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rQaHV3i
via IFTTT

Read More

US, Europe key export destinations for drug formulations, biologicals, surgical goods

India’s exports of surgical goods, drug formulations, and biologicals are gaining ground in US and European markets. The sector has shown substantial growth during April-August 2024. Exports to the US, UK, and other countries highlight India as a prominent global supplier of high-quality pharmaceutical and surgical products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/p6XGMbe
via IFTTT

Read More

Intermittent fasting: Who should avoid this popular eating pattern?

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OK56W3H
via IFTTT

Read More

Piyush Goyal holds meeting to address concerns of pharmaceutical exporters

Union Commerce Minister Piyush Goyal engaged with key pharmaceutical industry stakeholders, including the IMDA's General Secretary, to tackle challenges faced by pharmaceutical exporters and enhance India's position in the global market. The meeting highlighted collaborative efforts to address hurdles and maintain competitiveness in quality and pricing.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DTUwWGv
via IFTTT

Read More

SeaLink, promoter plan to sell majority stake in Surya Hospital

Private equity firm SeaLink Capital Partners and the Surya Children's Medicare promoter plan to sell their stakes in western India's largest children's hospital chain. Valued at ₹1,000-1,200 crore, JM Financial is managing the process, targeting global PE firms and leading Indian hospital chains for the acquisition.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SA4KlzD
via IFTTT

Read More

From Code to Care: How AI and hyperautomation can change patient care in India

Indian healthcare is being transformed by hyperautomation and other digital technologies. These advancements are improving patient care, reducing costs, and streamlining processes. Successful implementation requires collaboration between healthcare providers, government agencies, and tech companies. The shift towards digitisation is expected to overcome inefficiencies and create a more sustainable healthcare system for the future.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Km4h8vD
via IFTTT

Read More

Strides Pharma's OneSource raises Rs 801 crore in pre-listing round

OneSource Specialty Pharma, an associate of Strides Pharma, secured Rs. 801 crore from investors including HBM Healthcare Investments and WhiteOak Capital. With these funds, OneSource will reduce debt and enhance its manufacturing capabilities. The company aims to list its shares by March 2025 and targets being debt-free by FY26. Strides shareholders will benefit significantly from this transaction.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/MIlZQHG
via IFTTT

Read More

Government seeks dismissal of plea on Covishield deaths, Supreme Court to hear on November 26

The Supreme Court is hearing a plea from parents demanding an investigation into their daughters' deaths allegedly caused by Covishield vaccine. The government argues vaccination was voluntary and widely affirmed. The parents accuse the government of misleading the public and insufficiently addressing adverse effects.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/y681QIE
via IFTTT

Read More

Cipla, Alkem Laboratories in final lap to buy SMT

Promoters of SMT—the Kotadia family— plan to keep a minority stake after the transaction that would see other shareholders also divest their holdings. “They could retain about 15-20% stake post the deal,” said one of the persons cited above. Morgan Stanley PE Asia and Samara Capital collectively own 49% of SMT, while Kotak Pre-IPO Opportunities Fund has a 6% stake. The Kotadias own the remaining 45%.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/O743IdY
via IFTTT

Read More

Delhi HC allows Zydus Lifesciences to sell breast cancer drug Sigrima

The Delhi High Court division bench has allowed Zydus Lifesciences to sell its breast cancer drug Sigrima amidst accusations of it being similar to Roche's Perjeta. The court invalidated an earlier restraint order, noting no patent infringement by Zydus.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/eTvDiMN
via IFTTT

Read More

Marengo Asia eyes rights issue, stake sale to fund growth

Marengo Asia Healthcare plans to expand its bed capacity to 3,000 by 2026 and may involve an external investor. The platform has acquired multiple hospitals and is exploring further acquisitions and asset-light operation contracts. Currently, it operates with a 1,700-bed capacity and aims to reach an EBITDA margin above 20% in the next 12 to 18 months.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/OBAsU2b
via IFTTT

Read More

Turmeric for weight loss: 5 easy ways to shed pounds naturally

Turmeric, a golden spice known for its anti-inflammatory and antioxidant properties, can be a helpful addition to your weight loss routine. Rich in curcumin, turmeric boosts metabolism, aids digestion, and helps detoxify the body. Here are five ways to incorporate turmeric into your daily routine for effective weight management:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/XE6l8bs
via IFTTT

Read More

11 countries already recognise Indian pharmacopoeia as their standard: DCGI Rajeev Raghuvanshi

India is supplying drugs, vaccines, and medical devices to over 200 countries, with 11 countries recognizing Indian pharmacopoeia standards. The regulatory system is advanced, approving around 100 global clinical trials annually, and India's vaccine regulatory framework meets WHO global standards, bolstering its position as a significant international vaccine supplier.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dXGZcMU
via IFTTT

Read More

7 compelling reasons to add sweet potatoes to your diet

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8d3jB6O
via IFTTT

Read More

India reaffirmed its role as the pharmacy of the world during COVID: JP Nadda at International Conference of Drug Regulatory Authorities

Union Minister of Chemicals and Fertilisers JP Nadda, during his address at the 19th International Conference of Drug Regulatory Authorities (ICDRA), hailed India's crucial role during the Covid-19 pandemic and how the country is emerging as a global leader in health resilience and innovation, thereby reaffirming its position as the 'pharmacy of the world.'

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/uVCrfJL
via IFTTT

Read More

More health packages focused on elderly care likely to be added to AB-PMJAY

The National Health Authority is set to extend the Ayushman Bharat scheme to include those aged 70 and above, benefiting around six crore citizens. The scheme will offer expanded health packages focusing on geriatric care and provide free treatment up to Rs 5 lakh annually.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/9QOyAK3
via IFTTT

Read More

Glenmark arm recalls products in US for manufacturing issues

Glenmark Pharmaceuticals is recalling 45,504 bottles of Ryaltris Nasal Spray and 11,568 tubes of Ciclopirox Gel in the US due to manufacturing defects, including a clogged dip tube and broken tube seals. The USFDA has classified the recalls as Class II and Class III respectively.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/L0QbREr
via IFTTT

Read More

Star Health says it received $68k ransom demand after data leak

Star Health, India's largest health insurer, received a $68,000 ransom demand following a significant customer data leak. The hacker, using Telegram and a website, exposed sensitive information. The company has taken legal action and is cooperating with Indian cyber security authorities to identify the perpetrator.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/RDM3cOY
via IFTTT

Read More

PE firms queue up for Novartis' Indian arm

The PE firms are up against Dr Reddy's, which has an alliance with Novartis for marketing some of its off-patent products and is also expected to bid. Alkem Labs is also in the fray. Novartis India has a market capitalisation of around ?2,500 crore though bids are likely to value it lower, as per those in the know. Non-binding bids are due later this month.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3dqzuBg
via IFTTT

Read More

India's top drug regulator meets WHO standards for functional vaccine regulatory system

A WHO-led team reviewed India's vaccine regulatory system from September 16 to 20. The system was declared functional by meeting WHO's global standards and benchmarks. India's regulatory system has retained maturity level 3 with top marks in several functions. This achievement highlights India's significant role in the global pharmaceutical industry.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/oDfeaIQ
via IFTTT

Read More

No easy access for morning-after pill?

The government is considering a proposal requiring prescriptions for emergency contraception pills due to concerns about misuse and health risks. Experts argue that limiting access could result in more unwanted pregnancies, emphasizing the need for balanced information rather than restrictive measures.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/NbQCxj8
via IFTTT

Read More

Zydus gets US nod for schizophrenia generic medicine

Zydus Lifesciences has received the USFDA's final approval to produce a generic version of Paliperidone extended-release tablets, which are used to treat schizophrenia and schizoaffective disorders. The approval covers strengths of 1.5 mg, 3 mg, 6 mg, and 9 mg, with production set at the SEZ facility in Ahmedabad.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/DfHrg9w
via IFTTT

Read More

Rural households' out-of-pocket spend on hospitalisation stay Rs 4,129/yr, urban Rs 5,290: Govt Report

A government survey reported that the average out-of-pocket medical expenses for hospitalization over the past year were Rs 4,129 in rural areas and Rs 5,290 in urban areas. For non-hospitalization treatments in the last 30 days, the costs averaged Rs 539 in rural households and Rs 606 in urban ones.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/rSTCspQ
via IFTTT

Read More

QR code must for all vaccines to check fakes

The Indian government has mandated QR codes on all vaccines to combat counterfeiting and ensure authenticity. The Drug Controller General of India indicated an aggressive campaign against non-compliance, supported by strict enforcement and prosecution measures. Future expansions include QR code implementation on more products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/cGsxv9R
via IFTTT

Read More

Govt waives testing of cough syrups for export to key markets

India has waived off mandatory testing of cough syrups for export to countries like USA, UK, and EU if their regulatory authorities have approved the manufacturing plants. This change follows earlier requirements due to contamination concerns in Gambia and Uzbekistan. The Directorate General of Foreign Trade updated the export policy to reflect this exemption for specific approvals.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aTiEJl7
via IFTTT

Read More

Aurigene reports promising phase-1 data for its CAR-T therapy against myeloma

Aurigene Oncology has announced promising phase-1 results for its novel CAR-T cell therapy, Ribrecabtagene autoleucel, in patients with multiple myeloma. All patients achieved clinical response, with no high-grade safety events reported. The Indian drug regulator has approved the commencement of a phase-2 trial.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Hhc72ZO
via IFTTT

Read More

Are you making these 5 common fitness mistakes?

By being mindful of these common mistakes, you can enhance your fitness routine and work towards achieving your health goals more effectively.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hERP7Ys
via IFTTT

Read More

Ayushman Bharat to expand coverage for elderly healthcare to include Alzheimer's, Cancer, and more

Ayushman Bharat-Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) will expand to cover treatments for conditions like Alzheimer's, dementia, heart failure, and cancer in the elderly. This move aims to help six crore senior citizens, offering crucial healthcare access. A committee of medical experts is developing new packages to address these needs effectively.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/mR6rBJA
via IFTTT

Read More

7 flavorful foods rich in healthy fats for a healthier you

Here are seven foods packed with healthy fats that can enhance your diet:

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hTOampW
via IFTTT

Read More

Garmin, Apollo Hospitals join hands for health monitoring & wellness

Garmin and Apollo HealthAxis have partnered to bring advanced fitness tracking and personalized wellness programs to India. Garmin fitness trackers will be integrated with Apollo Health Plans, offering health monitoring and AI-powered health prediction. The collaboration also aims to improve healthcare in rural areas by combining Garmin's technology with Apollo's expertise.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/qCc7tVU
via IFTTT

Read More

Pharma companies seek more teeth for agencies to fight fakes

India's leading drug makers, through the Indian Pharmaceutical Alliance, have petitioned the Supreme Court to enable police and drug inspectors to investigate and prosecute counterfeit drug manufacturers. They argue that without proper enforcement and protection, the prevalence of counterfeit drugs has increased, affecting public health and India's global pharmaceutical reputation.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/aIjZTn7
via IFTTT

Read More

What lifestyle changes can help you stay cancer-free?

By adopting a healthier lifestyle and being proactive about your health, you can make a meaningful impact on your overall well-being.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/joznMk1
via IFTTT

Read More

ICMR to study efficacy of Metformin, Inositol in PCOS treatment

India's ICMR will study the efficacy of Metformin and Inositol drugs in improving fertility and birth outcomes in PCOS women. Despite widespread use, evidence on their effectiveness is limited, especially in the Indian context. The multi-centre study will address this knowledge gap.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/1fchZ23
via IFTTT

Read More

Detox dangers: Why you should reconsider

Detoxes lack scientific backing and may be unsafe due to poor regulation. Experts recommend consulting a healthcare professional for personalized, sustainable health solutions instead of relying on detox products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/8KVyroN
via IFTTT

Read More

Govt may mandate QR codes to check fake cancer drugs

The Indian government plans to require QR codes on all cancer drugs. This step aims to prevent counterfeit medicines and ensure drug authenticity. The Drugs Technical Advisory Board has agreed to the proposal. An amendment to the Drugs Rules, 1945, is necessary before implementation. This move follows earlier efforts to add barcodes on top 300 drug brands.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Zzn8X2y
via IFTTT

Read More

Lupin subsidiary acquires 9 brands South African firm

Lupin's subsidiary, in partnership with ImpiloVest, has acquired nine brands from MNI in South Africa, enhancing its portfolio in complementary and alternative medicines. The acquired brands address various health issues, aligning with Lupin's commitment to holistic and sustainable healthcare solutions.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/o6Pi3Za
via IFTTT

Read More

Quick access to key HIV drug hinges on waiver of local clinical trials: Experts

Faster access to HIV drug lenacapavir in India hinges on the waiver of local clinical trials. Six companies, including three from India, have non-exclusive, royalty-free licenses to produce generic versions. They must apply for waivers to supply the drug locally and in 120 low- and middle-income countries. Approval from the drug regulator is crucial.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/35L7eW2
via IFTTT

Read More

Emcure Pharmaceuticals partners with Gilead Sciences to produce HIV prevention drug Lenacapavir

Emcure Pharmaceuticals has partnered with Gilead Sciences Ireland UC to manufacture and distribute generic lenacapavir for HIV prevention and treatment. This royalty-free agreement focuses on increasing access to the drug in 120 countries, especially resource-limited nations. Emcure aims to provide high-quality, low-cost HIV medication to improve health outcomes globally.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/0jB2cKg
via IFTTT

Read More

CCI clears Rs 13,630 cr Mankind Pharma acquisition of Bharat Serums

The Competition Commission of India (CCI) has approved Mankind Pharma's ₹13,630-crore acquisition of Bharat Serums and Vaccines. This acquisition will strengthen Mankind's position in the Indian women's health and fertility drug market. Mankind Pharma and Bharat Serums both specialize in pharmaceutical formulations and healthcare products.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/WZEcsIU
via IFTTT

Read More

Dr Reddy's enters voluntary licensing deal with Gilead for long-acting HIV drug

Dr. Reddy’s has partnered with Gilead Sciences to manufacture and market the HIV drug Lenacapavir in India and 120 other countries. The agreement includes developing Lenacapavir for both treatment and potential prevention of HIV. This collaboration aims to make this advanced treatment accessible in regions with high HIV burdens.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/HZbqXu5
via IFTTT

Read More

CCI clears Rs 13,630-cr Mankind Pharma-Bharat Serums Vaccines deal

The Competition Commission of India has approved Mankind Pharma's Rs 13,630 crore acquisition of Bharat Serums and Vaccines. This acquisition, which includes a 100% stake, advances Mankind Pharma's position in the women's health and fertility drug market and grants access to critical care products with established R&D platforms.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bRyXsdU
via IFTTT

Read More